ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 1500

Work-Related Disability and Function in Systemic Lupus Erythematosus (SLE): Outcomes of an Exploratory Study from Different Canadian Centres

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 0878

YY1 a Potential Modulator of IL17/IL23 Axis in Psoriasis Disease

Cytokines & Cell Trafficking Poster

10:30AM-12:30PM: Abstract Number: 0877

Zasocitinib (TAK-279) Displays High Levels of TYK2 Inhibition and No Inhibition of JAK 1/3 Compared with Licensed TYK2 and JAK Inhibitors

Cytokines & Cell Trafficking Poster

10:30AM-12:30PM: Abstract Number: 1477

Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study

SpA Including PsA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1131

Zasocitinib (TAK-279), a Selective Oral Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis

Miscellaneous Rheumatic & Inflammatory Diseases Poster II

1:00PM-2:30PM: Abstract Number: 1683

68Ga-FAPI PET/CT Imaging for Assessing Renal Tubulointerstitial Fibrosis in Lupus Nephritis

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Biomarkers

1:00PM-2:30PM: Abstract Number: 1699

Anakinra in Giant Cell Arteritis: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: Clinical Trials

1:00PM-2:30PM: Abstract Number: 1671

Are Patient-reported Outcomes for Dactylitis, Uveitis, Psoriatic Skin and Nail Disease Valid in Patients with Psoriatic Arthritis?

Abstracts: Patient Outcomes, Preferences, & Attitudes I

1:00PM-2:30PM: Abstract Number: 1673

Assessing the Feasibility of a Mediterranean-Style Diet for Patients with Rheumatoid Arthritis in a Racially and Culturally Diverse Population Across the United States

Abstracts: Patient Outcomes, Preferences, & Attitudes I

1:00PM-2:30PM: Abstract Number: 1698

Assessment of the Remission Maintenance After Tocilizumab Withdrawal in Polymyalgia Rheumatica Patients Receiving a 6-month Treatment

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: Clinical Trials

1:00PM-2:30PM: Abstract Number: 1668

Association of Wearable-Sensor Derived Gait Measures with Widespread Pain over 2 Years: A Machine Learning Analysis in the Multicenter Osteoarthritis Study

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation

1:00PM-2:30PM: Abstract Number: 1684

Autoantibodies to Transcription Factor a Mitochondria Are Associated with Damage Accrual, Malignancy Risk and Mortality in SLE

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Biomarkers

1:00PM-2:30PM: Abstract Number: 1649

B Cell Subset Contribution to Autoantibodies in Lupus

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease II

1:00PM-2:30PM: Abstract Number: 1693

Change in Forced Vital Capacity at Week 12 or 24 Has Prognostic Value for Outcome at Week 52 in Patients with Autoimmune Disease-Related Interstitial Lung Diseases

Abstracts: Systemic Sclerosis & Related Disorders – Clinical I

1:00PM-2:30PM: Abstract Number: 1676

Changing Patients’ Mindsets About Non-Severe Side Effects of Methotrexate: A Randomized Controlled Trial

Abstracts: Patient Outcomes, Preferences, & Attitudes I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].